|
Pharmacological effects | Cell lines/model | Detail/mechanism(s) of action | Preparations/extracts/compounds | Application | Reference |
|
Anti-inflammatory effect | LPS-induced mouse acute lung injury | Increases levels of MPO and TNF-α; Inhibits the No level | Crude polysaccharides | In vivo | [66] |
Formalin-induced mice paw edema | Regulates the nicotinate and nicotinamide metabolism and arachidonic acid metabolism | Saikosaponins | In vivo | [5] |
LPS-stimulated RAW 264.7 cells | Regulates MAPK and NF-κB signals pathways | Saikosaponin a | In vitro | [68] |
LPS-stimulated human umbilical endothelial cells | Activates the LXRα-ABCA1 signaling pathway | Saikosaponin a | In vitro | [69] |
Septic rats model | Inhibits the nucleotide-binding oligomerization domain 2 (NOD2)/NF-κB signaling pathway | Saikosaponin a | In vivo | [70] |
LPS-induced apoptosis in human umbilical vein endothelial cells | Inhibits the caspase-3 activation and caspase-3-mediated-FAK degradation | Saikosaponin c | In vitro | [71] |
C6 rat glioma cells | Inhibits PGE2 production and elevates intracellular free Ca2+ concentration | Saikosaponin d | In vitro | [72] |
Monoclonal antibody induced nephritis | Suppresses proteinuria, proliferation of mesangial cells, and expansion of the mesangial matrix | Saikosaponin d | In vivo | [73] |
Chronic pancreatitis rats model | Inhibits the expression of NF-κB and TNF-α mRNA | Chai-hu-shu-gan powder | In vivo | [74] |
LPS-stimulated rat aorta and Raw 264.7 macrophages | Inhibits the NO production and iNOS protein expression | RCM-101 | In vivo/in vitro | [76] |
|
Anticancer effect | A549 human lung cancer cells | Suppresses telomerase activity and activates ERK 1/2 and caspase-3/9 | Acetone extracts | In vitro | [77–79] |
Human non-small-cell lung cancer A549 cells | Regulates Fas-dependent apoptotic pathway | Saponins | In vitro | [80] |
HepG2 hepatoma cells | Induces cell arrest at the late G1/early S phase | Water extracts | In vitro | [6] |
HepG2 cell line | Activates caspase-3 and caspase-7 | Saikosaponin d | In vitro | [81] |
SMMC-7721 cell line | Regulates the HIF-1α/COX-2 pathway | Saikosaponin d | In vitro | [82] |
HeLa and MCF-7 cancer cells | Inhibits the SERCA; Activates the CaMKKβ-AMP-AMPK-mTOR signaling cascade, ER stress and UPR | Saikosaponin d | In vitro | [43] |
|
Antiviral effect | H1N1-infected A549 cells | Anti-H1N1 virus | Acetone extracts | In vitro | [10] |
HBV-transfected human hepatoma cells | Inhibits DNA expression of HBsAg, HBeAg, and HBV | Saikosaponin c | In vitro | [81] |
HBV-transfected human hepatoma cells | Inhibits the production of HBV and the expression of HBeAg | Crude saponins | In vitro | [87] |
HBV-transfected human hepatoma cells | Inhibits DNA replication of HBV | MeOH extracts | In vitro | [88] |
Human coronavirus-229E | Interferes with the early stage of viral replication | Saikosaponins | In vitro | [89] |
|
Antipyretic effect | Dry yeast-induced high fever rats | Adjusts the synthesis and exudation of cAMP and AVP | Water extracts | In vivo | [90] |
Turpentine-induced fever rabbits | Decreases body temperature | The essential oil | In vivo | [91] |
Turpentine-induced fever rabbits and rats | Decreases body temperature | The essential oil | In vivo | [92] |
|
Antibacterial effect | Helicobacter pylori strain | Anti-Helicobacter pylori | Ethanol extracts | In vitro | [93] |
Staphylococcus aureus strain | Anti-Staphylococcus aureus | Chaihu injection | In vitro | [95] |
Pseudomonas aeruginosa, Listeria monocytogenes strains | Anti-Pseudomonas aeruginosa, Anti-Listeria monocytogenes | Saikosaponins | In vitro | [94] |
|
Hepatoprotective effect | CCl4 induced hepatic damage in rats | Hepatoprotective effects | Methanol extracts | In vivo | [96] |
D-galactosamine-induced hepatic injury in rats | Decreases the activity of glucose-6-phosphatase and NADPH-cytochrome C reductase; increases 5′-nucleotidase activity | Saikosaponins | In vivo | [97] |
D-galactosamine-induced cytotoxicity in rat hepatocytes | Hepatoprotective effects | Bupleurosides III, VI, IX, and XIII; saikosaponin b3 | In vitro | [98] |
BEL-7402 cells | Regulates intracellular calcium levels | Saikosaponins | In vitro | [99] |
CCl4 induced acute hepatic injury in rats | Hepatoprotective effects | Saikosaponin d | In vivo | [100] |
CR-1548 cell; liver fibrosis in rats | Reduces lipid peroxidation | Saikosaponin d | In vitro/in vivo | [101] |
|
Immunomodulatory effect | Rats fed with Radix Bupleuri | Increases the amplitude of spontaneous activity of lymphatic vessels | Water extracts | In vivo | [102] |
Human peripheral blood T cells | Inhibits CD28-costimulated activation | MeOH extracts | In vitro | [62] |
BALB/c, C3H/He and CDF1 mice | Stimulates T and B cells | Saikosaponin d | In vivo | [103] |
Thymocytes and spleen cells; C57BL/6 mice | Regulates receptor-bypassed pathway | Saikosaponin d | In vitro/in vivo | [41, 104, 105] |
|
Others | Male SD rats | Exhibits strong induction activity on the CYP2E1, CYP2D6, and CYP3A4 | Ethanol extracts | In vivo | [107] |
PTZ-induced epilepsy rats model | Inhibits mTOR signaling pathway | Saikosaponin a | In vivo | [109] |
THP-1 Cells | Inhibits PI3K/Akt/NF-κB/NLRP3 signaling pathway | Saikosaponin a | In vitro | [110] |
Human umbilical vein endothelial cells | Activates MMP-2, VEGF, and the p42/p44 mitogen-activated protein kinase | Saikosaponin c | In vitro | [111] |
SH-SY5Y and SK-N-SH cell lines | Suppresses the secretion of Aβ peptides | Saikosaponin c | In vitro | [112] |
Male Wistar rats | Increases the level of 5-HT and NE | Polyacetylenes | In vivo | [56] |
Dactylogyrus spp. infecting goldfish | Anthelmintic activity | Saikosaponins a and d | In vivo | [113] |
|